Dronedarone

證據等級: L5

預測適應症: 10 個

Dronedarone: From Atrial Fibrillation to Stroke Disorder

One-Sentence Summary

Dronedarone (brand name Multaq®) is a multichannel-blocking antiarrhythmic agent approved in the United States and European Union for atrial fibrillation (AF) and atrial flutter, used to reduce the risk of cardiovascular hospitalization and death. The TxGNN model predicts it may offer therapeutic benefit in stroke disorder, supported by 19 clinical trials and 20 publications currently covering this indication. With a prediction confidence of 99.97% and an evidence level of L2, this candidate warrants structured clinical evaluation.

Quick Overview

Item	Content
Original Indication	Atrial fibrillation / Atrial flutter (FDA/EMA-approved; not currently authorized in Canada)
Predicted New Indication	Stroke Disorder
TxGNN Prediction Score	99.97%
Evidence Level	L2
Canada Market Status	Not Marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Detailed mechanism of action data from Health Canada product monographs is not yet available for this assessment. Based on published clinical and pharmacological evidence, dronedarone is a non-iodinated amiodarone analogue that blocks multiple cardiac ion channels — sodium (Na⁺), potassium (K⁺), and calcium (Ca²⁺) — and exerts non-competitive anti-adrenergic activity. Its primary mechanism involves restoring and maintaining sinus rhythm in patients with paroxysmal or persistent AF, thereby reducing AF burden and the downstream risks associated with sustained irregular rhythm.

The link between dronedarone and stroke prevention is mechanistically well-grounded. AF is one of the strongest modifiable risk factors for cardioembolic stroke: atrial thrombi — most commonly in the left atrial appendage — can embolize to cerebral arteries and cause ischemic stroke. By controlling cardiac rhythm and reducing AF episodes, dronedarone attenuates the hemodynamic stasis and endothelial dysfunction that drive thrombus formation. The landmark EAST-AFNET 4 trial (NCT01288352, n=2,789) demonstrated that early rhythm control strategies — in which dronedarone was a principal antiarrhythmic agent — significantly reduced a composite cardiovascular endpoint that included stroke compared with usual care.

Beyond rhythm control, a key mechanistic study (PMID 28992468) demonstrated that dronedarone exerts direct anticoagulant and antiplatelet effects independent of its antiarrhythmic action, including inhibition of P-selectin expression, GPIIb/IIIa activation, and thrombin generation. This dual mechanism — rhythm normalization plus direct antithrombotic activity — provides a compelling biological rationale for the TxGNN prediction and helps explain the stroke reduction observed in the ATHENA post-hoc analysis (paroxysmal/persistent AF patients). The 2025 EAST-AFNET 4 sub-analysis (PMID 40387892) further confirmed long-term safety and efficacy of dronedarone for early rhythm control in reducing stroke-related outcomes.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01288352	Phase 4	Completed	2,789	EAST-AFNET 4: Early AF rhythm control (dronedarone as principal AAD) vs usual care; significantly reduced composite endpoint including stroke and cardiovascular death
NCT05293080	Phase 3	Not Yet Recruiting	1,746	EAST-STROKE: Evaluates early, comprehensive rhythm control (including dronedarone) in acute ischemic stroke patients with AF to prevent recurrent cardiovascular events; stroke is the primary endpoint
NCT07270848	Phase 4	Not Yet Recruiting	1,898	Prospective multicenter RCT directly evaluating dronedarone efficacy, safety, and quality of life for early rhythm control in AF (2026–2028); head-to-head vs alternative AAD
NCT05130268	Phase 4	Completed	339	Pragmatic RCT of early dronedarone vs usual care in first-detected AF; directly assesses outcomes including stroke prevention in a previously understudied AF population
NCT01151137	Phase 3	Terminated	3,236	PALLAS trial: Dronedarone 400 mg BID in permanent AF with additional stroke risk factors; terminated early due to increased rates of stroke, HF hospitalization, and cardiovascular death — critical safety reference for patient selection
NCT01856075	Observational	Completed	1,015	International real-world cohort (Germany, Spain, Italy, USA) comparing dronedarone vs other AADs for AF in clinical practice; stroke as secondary effectiveness endpoint
NCT05279833	SLR/NMA	Completed	87,810	Systematic literature review and network meta-analysis comparing dronedarone vs sotalol safety and effectiveness across interventional and observational studies in AF
NCT01266681	N/A	Unknown	100	Head-to-head: Amiodarone vs dronedarone for sinus rhythm maintenance after DC cardioversion in persistent AF; indirect evidence for rhythm control capacity
NCT04704050	Phase 4	Terminated	22	EDORA: Dronedarone vs placebo post-cardiac ablation — effect on atrial fibrosis progression and AF recurrence; provides mechanistic insight into structural cardiac remodeling
NCT02618577	Phase 3	Terminated	2,608	NOAH-AFNET 6: NOAC (edoxaban) vs usual care for AF high-rate episodes; dronedarone used as background rhythm control; stroke was a secondary endpoint

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40387892	2025	RCT Post-hoc Analysis	Clinical Research in Cardiology	Long-term safety and outcomes of dronedarone and amiodarone in EAST-AFNET 4 early rhythm control; confirms dronedarone’s contribution to stroke endpoint reduction with acceptable safety
28992468	2017	Mechanistic Study	Atherosclerosis	Dronedarone inhibits P-selectin, GPIIb/IIIa, and thrombin generation independently of antiarrhythmic effects, providing a direct antithrombotic mechanism relevant to stroke prevention
28496906	2013	Cohort Study	Journal of Atrial Fibrillation	Real-world US retrospective cohort (n=10,455): Dronedarone vs amiodarone and other AADs — comparative risk of stroke, CHF, interstitial lung disease, and acute liver injury
37485722	2023	Retrospective Cohort	Circulation: Arrhythmia and Electrophysiology	Dronedarone vs sotalol in AAD-naïve veterans with AF: dronedarone did not require QT monitoring and demonstrated comparable sinus rhythm maintenance without excess arrhythmia risk
35293087	2022	RCT Post-hoc Analysis	European Journal of Heart Failure	ATHENA post-hoc: Dronedarone reduced cardiovascular events in AF patients with concomitant HFpEF/HFmrEF — expands target population beyond systolic dysfunction
22082198	2011	Phase 3 RCT (PALLAS)	New England Journal of Medicine	PALLAS trial: Dronedarone significantly increased stroke, HF hospitalization, and death in permanent AF — establishes the critical contraindication boundary for stroke indication
20730068	2010	Review	Vascular Health and Risk Management	Comprehensive review of dronedarone FDA approval; ATHENA post-hoc analysis showed significant reduction in stroke and TIA in paroxysmal/persistent AF patients
22433576	2012	Clinical Guideline	Canadian Journal of Cardiology	Canadian Cardiovascular Society 2012 AF guideline focused update — includes dronedarone in recommendations for stroke prevention and rhythm control strategy selection
24469871	2013	Review	Cardiology Journal	Clinical practice review of dronedarone efficacy and tolerability in AF: summarizes major trial data including ATHENA, DIONYSOS, ANDROMEDA, and PALLAS
22920480	2012	Review	Current Cardiology Reviews	Stroke prevention in AF: evolving strategies including rhythm control agents and novel anticoagulants; contextualizes dronedarone’s role within the antithrombotic landscape

Safety Considerations

Please refer to the package insert for safety information.

Critical Evidence-Based Caution: The PALLAS trial (NCT01151137, published in NEJM 2011, PMID 22082198) was terminated early because dronedarone significantly increased stroke, heart failure hospitalization, and cardiovascular death in patients with permanent AF. This is a well-established class contraindication: dronedarone must only be used in non-permanent (paroxysmal or persistent) AF. Any stroke-prevention indication must rigorously exclude patients with permanent AF. Additionally, dronedarone inhibits P-glycoprotein and CYP3A4, increasing plasma concentrations of co-administered direct oral anticoagulants (DOACs) — a pharmacokinetic interaction requiring dose adjustment and monitoring (PMID 41152878, 27693025).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The EAST-AFNET 4 trial (n=2,789, completed Phase 4) and the post-hoc ATHENA analysis provide convergent evidence that dronedarone, as part of early rhythm control in non-permanent AF, significantly reduces stroke and cardiovascular events. The dual mechanism of rhythm normalization plus direct antithrombotic activity (PMID 28992468) and the inclusion of dronedarone in the 2012 Canadian Cardiovascular Society AF guidelines support the scientific credibility of this repurposing prediction. Evidence meets the L2 threshold. However, the PALLAS safety signal mandates careful patient selection and guardrails.

To proceed, the following is needed:

Obtain the Health Canada product monograph (once/if authorized) to confirm Canadian-specific indication language, warnings, and contraindications
Apply the PALLAS exclusion rule rigorously: dronedarone is contraindicated in permanent AF — any stroke indication must target paroxysmal or persistent AF only
Define the precise target population using EAST-AFNET 4 and ATHENA stroke sub-population data (early AF diagnosis, ≥1 cardiovascular comorbidity, no permanent AF)
Evaluate the clinical significance of the dronedarone–DOAC pharmacokinetic interaction (P-gp inhibition elevating DOAC levels) given that AF stroke-prevention regimens commonly combine antiarrhythmic and anticoagulant drugs
Monitor emerging data from NCT05293080 (EAST-STROKE, n=1,746) and NCT07270848 (Phase 4 RCT, n=1,898) — both expected to provide direct evidence in the stroke population by 2028–2029
Pursue Health Canada Drug Identification Number (DIN) application as a prerequisite for Canadian market access
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.